Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Basit Öğe Kaydı
dc.authoridalan, ozkan/0000-0002-6635-2012
dc.authoridPaksoy, Nail/0000-0003-4636-2595
dc.authoridAkyildiz, Arif/0000-0002-4452-2076
dc.authorwosidalan, ozkan/AAV-5044-2020
dc.authorwosidARAK, Haci/KIB-6642-2024
dc.authorwosidPaksoy, Nail/HKF-3015-2023
dc.authorwosidbir yucel, kadriye/HGE-4410-2022
dc.authorwosidAkyildiz, Arif/IQW-4417-2023
dc.contributor.authorUnal, Caglar
dc.contributor.authorSelcuk, Nalan Alan
dc.contributor.authorBiricik, Fatih Selcuk
dc.contributor.authorAlan, Ozkan
dc.contributor.authorOrdu, Cetin
dc.contributor.authorSelvi, Oguzhan
dc.contributor.authorSakin, Abdullah
dc.date.accessioned2024-06-12T11:07:55Z
dc.date.available2024-06-12T11:07:55Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjectives: This study aimed to evaluate the clinical outcomes, including progression-free survival (PFS), overall sur-vival (OS), Objective Response Rate (ORR), and Disease Control Rate (DCR), in patients received Lutetium-177 (Lu-177) DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) for metastatic neuroendocrine tumors. This study further stratified outcomes based on tumor grade, Ki-67 status, primary tumor localization, number of treatment cycles, and associated adverse effects.Methods: We conducted a multicenter retrospective study analyzing the data of 73 patients with metastatic NETs across 17 different hospitals in various regions of Turkiye. A total of 73 metastatic NET patients underwent Lu-177 DOT-ATATE PRRT between December 2013 and March 2023. Results: Over a median follow-up of 52.7 months, patients showed a median PFS of 13.7 months and OS of 51.2 months. The ORR was 29.6%, and the DCR was 66.2%. Grade 1 and 2 tumor patients had superior outcomes (PFS: 16.9 months, OS: 55.5 months) compared to grade 3 tumor patients (PFS: 8.5 months, OS: 29.5 months). Based on their Ki-67 status, those <= 20% had prolonged PFS (16.9 months) and OS (55.5 months) than those between 21 and 55% (PFS: 5.9 months, OS: 41.3 months). Regarding primary tumor localization, the PFS values were 13.1, 15.3, 13.7, and 8.6 months for pancreatic, GIS, lung, and unknown origin tumors, respectively. The OS across tumor types fluctuated between 41.1 and 54.1 months. Patients who received more than four cycles demonstrated significantly improved median PFS (22.4 months) and OS (90.3 months) compared to those who received <= 4 cycles (median PFS: 9.3 months; median OS: 41.8 months). Grade 3-4 adverse effects were observed in 21.9% of patients.Conclusion: Our findings affirm that PRRT is a potent and well-tolerated treatment for metastatic NETs. Notably, pa-tients who received more than 4 cycles of PRRT experienced a markedly improved median PFS and OS compared to their counterparts who received <= 4 cycles.en_US
dc.identifier.doi10.14744/ejmo.2023.48337
dc.identifier.endpage242en_US
dc.identifier.issn2587-196X
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85175379046en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage232en_US
dc.identifier.urihttps://doi.org/10.14744/ejmo.2023.48337
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22239
dc.identifier.volume7en_US
dc.identifier.wosWOS:001135942300003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherKare Publen_US
dc.relation.ispartofEurasian Journal Of Medicine And Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLutetium-177en_US
dc.subjectNeuroendocrine Tumorsen_US
dc.subjectNeuroendocrine Neoplasmen_US
dc.subjectPeptide Receptor Radionuclide Therapyen_US
dc.subjectPRRTen_US
dc.subjectRadiolabeled Somatostatin Analoguesen_US
dc.subjectEnets Consensus Guidelinesen_US
dc.subjectPrognostic-Factorsen_US
dc.subjectTyr(3) Octreotateen_US
dc.subjectHigh-Gradeen_US
dc.subjectLu-177-Dotatateen_US
dc.subjectSurvivalen_US
dc.subjectG3en_US
dc.subjectEpidemiologyen_US
dc.subjectEfficacyen_US
dc.titleAssessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiyeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu